Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 06, 2026, titled "USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The USFDA conducted a GMP surveillance inspection at Zydus' Unit 9 facility (Biologics Injectable plant) in Ahmedabad from April 27 to May 5, 2026. The inspection concluded with seven observations being raised. Importantly, there were no data integrity related observations, which is a positive aspect. The company has stated it will work closely with the USFDA to address these observations. This disclosure is made under SEBI's Listing Obligations and Disclosure Requirements Regulation 30.
The seven observations indicate compliance gaps at the injectable manufacturing facility, which could delay or impact future product approvals for the US market. While not a warning letter, investors should monitor how quickly Zydus resolves these issues as it may affect revenue from the US biologics business.